ABDXF (Abingdon Health) Intrinsic Value: Projected FCF: $-0.15 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABDXF Abingdon Health PLC ABDXF
49 GF Score
Price $0.15
GF Value $0.21
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Abingdon Health Intrinsic Value: Projected FCF?

Abingdon Health ABDXF 49 Intrinsic Value: Projected FCF is $-0.15 as of Aug. 28, 2026. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 952380% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-08-28), Abingdon Health's Intrinsic Value: Projected FCF is $-0.15. The stock price of Abingdon Health is $0.149. Therefore, Abingdon Health's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Abingdon Health's Intrinsic Value: Projected FCF or its related term are showing as below:

ABDXF's Price-to-Projected-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.5
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Abingdon Health  (OTCPK:ABDXF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Abingdon Health's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.149/-0.15278728776007
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abingdon Health Intrinsic Value: Projected FCF Related Terms


Abingdon Health Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Abingdon Health's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abingdon Health Intrinsic Value: Projected FCF Chart

Abingdon Health Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.09 -0.11

Abingdon Health Semi-Annual Data
Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.09 0.00 -0.11 0.00

ABDXF vs TMO, DHR, IDXX: Intrinsic Value: Projected FCF Comparison

For the Diagnostics & Research subindustry, Abingdon Health's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abingdon Health Price-to-Projected-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Abingdon Health's Price-to-Projected-FCF falls into.


ABDXF
49GF Score
Abingdon Health PLC ABDXF
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abingdon Health Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Abingdon Health's Free Cash Flow(6 year avg) = $-6.49.

Abingdon Health's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun25)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-6.4885714285714+7.191*0.8)/366.658
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of $-0.15 mean?
Abingdon Health (ABDXF) has a Intrinsic Value: Projected FCF of $-0.15 as of Aug. 28, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Abingdon Health and its competitors. According to the industry distribution chart, Abingdon Health ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is Abingdon Health's Intrinsic Value: Projected FCF too high?
Abingdon Health's current Intrinsic Value: Projected FCF is $-0.15. Based on the distribution chart, Abingdon Health ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Intrinsic Value: Projected FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #999999 out of 105 companies for Intrinsic Value: Projected FCF. This places Abingdon Health in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Diagnostics & Research company?
The median Intrinsic Value: Projected FCF among Medical Diagnostics & Research companies is 1.50, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Intrinsic Value: Projected FCF is $-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 29% below its estimated fair value. The current Intrinsic Value: Projected FCF is $-0.15. Abingdon Health's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Intrinsic Value: Projected FCF is $-0.15 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abingdon Health (ABDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued. The current stock price of $0.15 is trading 29% below its estimated GF Value™ of $0.21. GuruFocus considers Abingdon Health to be Modestly Undervalued.

Key valuation signals for ABDXF:

  • Intrinsic Value: Projected FCF: $-0.15
  • GF Value™: $0.21 vs. price of $0.15 (29% below fair value)
  • GF Score™: 49/100 with 9 warning signs

No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abingdon Health Business Description

Other Exchanges ABDX:UK
Address York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score

Get the complete analysis for ABDXF

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.21
GF Value